Aristea Translational Medicine Corp. is a Utah-based small business. Since its incorporation in 2000, with others located at the National Institute on Aging, NIH, and at U.S., Canadian, and U.K. universities, Aristea has investigated the sources of failures in therapeutic drug developments and methods for overcoming unnecessary failures.
Beginning in 2010, with investigators at the National Institute on Aging, Aristea turned its expertise in drug development to clinical pharmacological research that has led to the use of PhenT and its proposed applications for preventing cell dysfunction and death in COVID-19 disease.
With the support of Aristea and a $4 million, five-year grant from the National Institute of Aging, collaborators at the University of Southern California, U.S. and at the University of Exeter, U.K. are carrying out clinical trials testing PhenT as a treatment to arrest progression in Alzheimer's disease. Aristea has PhenT patents and patents pending and emphasizes that this is an opportunity announced only to facilitate empirical evaluation.
